Gallo to Establish a Major AIDS Institute

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

BETHESDA, Md--One of the discoverers of HIV, Robert C. Gallo, MD, is leaving the National Cancer Institute after 30 years, most recently as head of the Division of Tumor Cell Biology.

BETHESDA, Md--One of the discoverers of HIV, Robert C. Gallo,MD, is leaving the National Cancer Institute after 30 years, mostrecently as head of the Division of Tumor Cell Biology.

He will establish a major AIDS research institute at the Universityof Maryland, Baltimore, to be called the Institute of Human Virology.The institute will be supported by at least $9 million in Marylandtax revenues for the first 3 years and will receive an additional$3 million in Baltimore city funds, Dr. Gallo said.

It eventually will employ 250 people and have an annual budgetof $25 million to $30 million, including government grants andcollaboration with private industry.

Two top scientists accompanying Dr. Gallo to Baltimore are WilliamBlattner, MD, chief of the NCI's Viral Epidemiology Branch, andRobert Redfield, MD, a clinical virologist at the Walter ReedArmy Institute of Research.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content